|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS |
|
|
|
 |
|
|
PROfound Study - PARP-inhibitor Olaparib in Advanced Prostate Cancer Patients with Specific Tumor Mutations
|
|
Maha Hussain, MD, FACP, FASCO
|
| Maha Hussain joins Alicia Morgans sharing an overview of the PROfound study design. The trial was intended to look at the second line setting and the intent was to capture patients who may be less likely to respond to AR targeted drugs or who were not potential chemotherapy candidates.
|
|
|
|
|
|
|
|
|
|
 |
|
|
DNA Repair Defects in Metastatic Prostate Cancer
|
|
Elena Castro, MD
|
| Elena Castro discusses her recent publication in Journal Clinical Oncology on DNA repair defects in prostate cancer. The primary objective of the study was to determine whether mutations in BRCA 1, BRCA 2, ATM and PALB 2 would affect survival in patients diagnosed with mCRPC.
|
|
|
|
|
|
|
|
|
|
 |
|
|
PARP Inhibition for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presentation
|
|
Kim Chi, MD, FRCPC
|
| Kim Chi presented an update on the utilization of PARP inhibitors during the Management of Castration-Resistant Prostate Cancer (CRPC) session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Leading his presentation with the most recent positive phase III results from Lynparza® (olaparib), the only PARP inhibitor with positive phase III results in four different cancer types.
|
|
|
|
|
|
|
|
|
|
 |
|
| Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines - Oliver Sartor
|
| A. Oliver Sartor, MD
|
| A. Oliver Sartor discusses his contributions to the recent publication in JAMA Oncology on the prevalence of germline variants in prostate cancer and the implications for genetic testing guidelines.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EDITOR SELECTED ABSTRACTS AND COMMENTARIES |
|
|
|
|
| PROfound: Phase 3 Study of Olaparib vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations
|
| Maha Hussain, MD
|
| PROfound was a randomized, open-label, phase III trial evaluating efficacy and safety of olaparib vs enzalutamide or abiraterone in patients with mCRPC with alterations in any of 15 predefined genes with a direct or indirect role in homologous recombination repair whose disease had progressed on prior new hormonal agent therapy. At the Presidential session at ESMO 2019, Dr. Maha Hussain and colleagues presented the initial results of PROfound.
|
|
|
|
|
|
| GALAHAD - A Phase 2 Study of Niraparib in Patients with mCRPC and Biallelic DNA-Repair Gene Defects, A Pre-Specified Interim Analysis
|
| Matthew R. Smith, MD, Ph.D
|
| Patients with metastatic castration-resistant prostate cancer (mCRPC) and disease progression after androgen receptor (AR) targeted therapy and taxane-based chemotherapy have a poor prognosis and few options for treatment. Preliminary evidence suggests that PARP inhibition is effective for patients with mCRPC and DNA repair defects (DRD). Niraparib is a highly selective PARP inhibitor with activity against the PARP-1 and PARP-2 DNA-repair polymerases and is approved as maintenance therapy for recurrent ovarian cancer.
|
|
|
|
|
|
| Pembrolizumab Plus Olaparib in Docetaxel-Pretreated Patients with mCRPC: Cohort A of KEYNOTE-365 Study
|
| Evan Y. Yu, MD
|
| In this presentation, data from cohort A (pembrolizumab+olaparib) of the KEYNOTE-365 is presented. KEYNOTE-365 is a phase 1b/2 non-randomized, multicenter, multicohort, open-label umbrella study to test various pembrolizumab combinations in mCRPC patients.
|
|
|
|
|
|
|
|
|
|
|
| CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, PARP inhibitors, and PD1 inhibitors
|
| Emmanuel Antonarakis, MBBCh
|
| Although once considered a homologous recombination DNA repair gene, CDK12 is now thought to have a distinct role in maintaining genomic stability. In prostate cancer, inactivating CDK12 mutations lead to gene fusion-induced neoantigens, which may result in sensitivity to immunotherapeutic treatment strategy. The authors of this abstract conducted a retrospective, multicenter study to identify advanced prostate cancer patients with loss-of-function CDK12 alterations.
|
|
|
|
|
|
| Final Analysis of LATITUDE, A Phase III in Patients with Newly Diagnosed High-risk Metastatic Castration-naïve Prostate Cancer
|
| Kim N. Chi, MD
|
| Dr. Chi presents the final analysis of the LATITUDE phase III study, a phase III randomized, clinical trial that evaluated the efficacy of abiraterone acetate and prednisone with androgen deprivation therapy (ADT) in men with newly-diagnosed, castration sensitive, metastatic prostate cancer.
|
|
|
|
|
|
